Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Danielle C. Glassman"'
Autor:
Danielle C. Glassman, Randze L. Palmaira, Christina M. Covington, Avni M. Desai, Geoffrey Y. Ku, Jia Li, James J. Harding, Anna M. Varghese, Eileen M. O’Reilly, Kenneth H. Yu
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
Abstract Background Effective treatment options for advanced pancreatic cancer are finite. NAPOLI-1, a phase III randomized trial, demonstrated the efficacy of nanoliposomal irinotecan with fluorouracil/leucovorin (nal-IRI + 5-FU/LV) for the treatmen
Externí odkaz:
https://doaj.org/article/d76611a5fe52415d8c44ebc634314e01
Autor:
H. Chintalapudi, Smrita Sinha, Christine A. Iacobuzio-Donahue, Jonathan Bermeo, V. Aveson, Richard A. Moffitt, A. Cardenas, Lance Zhang, S. Laderman, Vinod P. Balachandran, Kenneth H. Yu, Danielle C. Glassman, Rohit Chandwani, Nicolas Lecomte, D. Torres, Christina S. Leslie, Steven D. Leach, B. Curry, Gokce Askan, Jerry P. Melchor, S. Leppanen, A. L. Massa, Sagar Chhangawala, Jiang Gui, Surajit Dhara, Alvin Makohon-Moore, Rémy Nicolle
We investigated tumor-cell-intrinsic chromatin accessibility patterns of pancreatic ductal adenocarcinoma (PDAC) by ATAC-seq on EpCAM+ PDAC malignant epithelial cells, sorted from 54 freshly resected human tumors, and discovered a signature of 1092 c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b4a9239cf47239cc8efaa23399acc80b
https://doi.org/10.1101/2021.01.21.427604
https://doi.org/10.1101/2021.01.21.427604
Autor:
Christina S. Leslie, A. Cardenas, S. Leppanen, Rohit Chandwani, Lance Zhang, Smrita Sinha, S. Laderman, Danielle C. Glassman, Sagar Chhangawala, V. Aveson, Nicolas Lecomte, Steven D. Leach, D. Torres, Vinod P. Balachandran, Jiang Gui, Surajit Dhara, Richard A. Moffitt, Kenneth H. Yu, Alvin Makohon-Moore, B. Curry, Gokce Askan, Rémy Nicolle, H. Chintalapudi, Christine A. Iacobuzio-Donahue, A. L. Massa, Jonathan Bermeo, Jerry P. Melchor
Publikováno v:
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-9 (2021)
Nature Communications, Vol 12, Iss 1, Pp 1-9 (2021)
Unlike other malignancies, therapeutic options in pancreatic ductal adenocarcinoma (PDAC) are largely limited to cytotoxic chemotherapy without the benefit of molecular markers predicting response. Here we report tumor-cell-intrinsic chromatin access
Autor:
Eileen M. O'Reilly, Xiaoxing Feng, Adalberto Barba, David P. Kelsen, Ellen Hollywood, Ghassan K. Abou-Alfa, Danielle C. Glassman, M. Capanu, John S. Bomalaski, James J. Harding, Maeve A. Lowery, Christina M. Covington, Amanda Johnston, Kenneth H. Yu, Kay Chia Wei Liu, Robin Brenner
Publikováno v:
Cancer. 123:4556-4565
BACKGROUND ADI-PEG 20 is a pegylated form of the arginine-depleting enzyme arginine deiminase. Normal cells synthesize arginine with the enzyme argininosuccinate synthetase (ASS1); ADI-PEG 20 selectively targets malignant cells, which lack ASS1. METH
Publikováno v:
American Journal of Obstetrics and Gynecology. 222:S193-S194
Autor:
Avni M. Desai, James J. Harding, Geoffrey Y. Ku, Danielle C. Glassman, Randze Lerie Palmaira, Anna M. Varghese, Eileen M. O'Reilly, Christina M. Covington, Jia Li, Kenneth H. Yu
Publikováno v:
BMC Cancer
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
Background Effective treatment options for advanced pancreatic cancer are finite. NAPOLI-1, a phase III randomized trial, demonstrated the efficacy of nanoliposomal irinotecan with fluorouracil/leucovorin (nal-IRI + 5-FU/LV) for the treatment of adva
Autor:
David B. Solit, Brian Herbst, Olca Basturk, Gokce Askan, Peter J. Allen, Eileen M. O'Reilly, Emmet Jordan, Christine A. Iacobuzio-Donahue, Mark A. Schattner, Ryan Ptashkin, Kenneth H. Yu, Tanisha Leach, David S. Klimstra, William R. Jarnagin, Michael F. Berger, Anna M. Varghese, Maeve A. Lowery, Ghassan K. Abou-Alfa, James J. Harding, Ahmet Zehir, Steven D. Leach, Leonard B. Saltz, David M. Hyman, Hannah Maynard, Jaclyn F. Hechtman, Nikolaus Schultz, Danielle C. Glassman, Christina M. Covington, Vinod P. Balachandran
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(20)
Purpose: Molecular profiling in cancer has identified potential actionable drug targets that have prompted attempts to discover clinically validated biomarkers to guide therapeutic decision-making and enrollment to clinical trials. We evaluated wheth
Autor:
Maeve A, Lowery, Kenneth H, Yu, David Paul, Kelsen, James J, Harding, John S, Bomalaski, Danielle C, Glassman, Christina M, Covington, Robin, Brenner, Ellen, Hollywood, Adalberto, Barba, Amanda, Johnston, Kay Chia-Wei, Liu, Xiaoxing, Feng, Marinela, Capanu, Ghassan K, Abou-Alfa, Eileen M, O'Reilly
Publikováno v:
Cancer. 123(23)
ADI-PEG 20 is a pegylated form of the arginine-depleting enzyme arginine deiminase. Normal cells synthesize arginine with the enzyme argininosuccinate synthetase (ASS1); ADI-PEG 20 selectively targets malignant cells, which lack ASS1.A single-arm, no
Autor:
Sagar Chhangawala, Gokce Askan, Surajit Dhara, Christina S. Leslie, Zhang Liguo, Kenneth H. Yu, Danielle C. Glassman, Steven T. Leach, Smrita Sinha, Vinod P. Balachandran
Publikováno v:
Cancer Research. 78:LB-238
We have recently discovered a set of 1092 cis-regulatory elements in the human genome that are differentially accessible in the treatment-naïve resected subset of pancreatic ductal adenocarcinoma (PDAC) recurring within first 12 months of surgery. R
Autor:
James J. Harding, Jia Li, Danielle C. Glassman, Eileen M. O'Reilly, Avni M. Desai, Kenneth H. Yu, Geoffrey Y. Ku, Anna M. Varghese
Publikováno v:
Journal of Clinical Oncology. 36:471-471
471 Background: Therapy options for advanced pancreatic adenocarcinoma (PDAC) are finite. NAPOLI-1, a phase III randomized trial, demonstrated the efficacy of N+F following progression on gemcitabine (G) based therapy (mPFS 3.1 mo, mOS 6.1 mo). There